Effects of pegylated interferon on cellular immune function in patients with chronic hepatitis C
10.3969/j.issn.1005-1678.2017.07.020
- VernacularTitle:聚乙二醇干扰素治疗慢性丙肝患者对于机体细胞免疫功能的影响
- Author:
Yang SHEN
;
Haiyan WU
- Keywords:
chronic hepatitis C;
pegylated interferon;
clinical efficacy;
cellular immune function;
influence effect
- From:
Chinese Journal of Biochemical Pharmaceutics
2017;37(7):57-58
- CountryChina
- Language:Chinese
-
Abstract:
Objective To investigate the clinical effect of pegylated interferon(IFN)on chronic hepatitis C and its effect on cellular immune function.Methods A total of 92 patients with chronic hepatitis C were enrolled in our hospital from June 2013 to October 2016.They were randomly divided into study group and control group by single and double numbers(admission order),with 46 cases in each group.The control group was treated with recombinant human interferon alpha-2b on the basis of conventional treatment.The study group was treated with pegylated interferon alpha-2a on the basis of conventional treatment.Results After treatment, the rates of RVR, EVR, ETVR and SVR in the study group(52.17%, 71.74%, 76.09% and 54.35%, respectively)were significantly higher than those in the control group(34.78%, 50%, 58.70%, 39.13%, respectively), The difference was statistically significant(P<0.05).There were no significant difference in the cellular immune function index between the two groups before treatment;After treatment,the CD3+, CD4+, CD4+/CD8+ and other immune function indexes of the study group were significantly higher than those before treatment, while the results of CD8+ were significantly lower than before treatment(P<0.05);There was no significant difference in the cellular immune function in the control group compared with before, and the difference of the cellular immune function between the 2 groups after treatment was statistically significant(P<0.05).Conclusion Pegylated interferon(IFN)on the basis of routine treatment can improve the virologic response and cellular immune function in patients with chronic hepatitis C.
